Solifenacin, approved by the U.S. FDA in 2004, is a medication primarily used to treat overactive bladder (OAB) symptoms such as frequent urination, urgency, and incontinence. It belongs to the class of drugs known as antimuscarinics, which work by blocking the action of acetylcholine, a neurotransmitter that stimulates bladder muscles. 

Solifenacin has been extensively studied through clinical trials and has proven effective in managing symptoms of OAB. It provides patients with better bladder control and improved quality of life. The drug is marketed under various brand names and has shown favourable results in long-term treatment for urinary disorders.

• Treatment of overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence.
• Management of neurogenic detrusor overactivity in patients with spinal cord injury or multiple sclerosis.

Solifenacin is typically administered orally in the form of tablets. The recommended starting dose is usually 5 mg once daily, which can be increased to 10 mg depending on the patient’s response and tolerance. It is important to take the tablet with or without food, as directed by your healthcare provider. The dosage may be adjusted for patients with specific medical conditions, such as renal or hepatic impairment.

Serious Side Effects:

• Severe allergic reactions (e.g., rash, itching, swelling, dizziness)
• Difficulty swallowing or breathing
• Signs of a urinary tract infection (e.g., painful urination, fever)

Common Side Effects:

• Dry mouth
• Constipation
• Blurred vision
• Dizziness
• Headache
• Fatigue

While side effects are generally mild, patients should report any severe or persistent symptoms to their healthcare provider immediately.

• Solifenacin should not be used in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or severe liver disease.
• Patients taking strong CYP3A4 inhibitors (e.g., ketoconazole) should avoid using this drug due to the risk of increased solifenacin levels in the bloodstream.
• Caution is advised for individuals with a history of arrhythmias, as the drug can increase the risk of QT interval prolongation.

When administering solifenacin, it’s important to ensure the patient’s medical history is reviewed, especially regarding conditions like kidney disease, liver problems, or glaucoma. Since the drug can cause dry mouth, blurred vision, and constipation, it is crucial to assess the patient’s ability to tolerate these side effects. Patients with a history of urinary retention should be closely monitored as the drug could exacerbate this condition. Pregnant or breastfeeding women should consult their doctor before using solifenacin, as its safety in these cases has not been established.

To minimise side effects, it is recommended to stay hydrated and manage any signs of constipation by increasing fibre intake. Patients should avoid alcohol, as it can increase drowsiness and dry mouth. It's crucial to follow the prescribed dosage and schedule to maximise the drug's effectiveness and minimise the risk of side effects. Additionally, patients with kidney or liver impairments should have their dosage closely monitored.

1. https://www.nhs.uk/medicines/solifenacin/
2. https://go.drugbank.com/drugs/DB01591
3. https://www.nhs.uk/medicines/solifenacin/about-solifenacin/

This content is intended for informational purposes only and should not replace medical advice from a healthcare professional. Always consult your doctor or pharmacist before starting any new medication.